BBIO’s Analyst Rating: Morgan Stanley Initiates Coverage with Overweight

Jan 6, 2026
bbio’s-analyst-rating:-morgan-stanley-initiates-coverage-with-overweight

Key Takeaways

Morgan Stanley initiates coverage on BridgeBio Pharma (BBIO) with an “Overweight” rating. Price target announced at $96.00 USD.Morgan Stan

  • Latest
  • Popular

CONNECT & FOLLOW

SPECIAL POST

Elon Musk

Leave a comment